Secukinumab resistance management

A retrospective multicenter observational study included psoriatic arthritis (PsA) patients with a history of secukinumab who were further treated with ixekizumab. The primary endpoint was primary response to treatment (drug survival> 6 months); secondary endpoints were change in disease activity index from initiation of ixekizumab to 6 and 12 months later and overall drug survival.

Patients with drug-resistant PsA, including those who had an inadequate response to secukinumab, showed good, albeit limited, responses to ixekizumab. In PsA patients who fail secukinumab, intraclass switching from secukinumab to ixekizumab may be a reasonable treatment option. Everyone’s constitution is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.